It is currently Fri Dec 09, 2016 1:40 am

News News of Drug Pipeline

Site map of Drug Pipeline » Forum : Drug Pipeline

A board to discuss future MS therapies in early stage (Phase I or II) trials.

Winter_2006_Progress_Summary from MRF

I had mailed Myelin Reasearch Foundation (MRF) about their winter progress update on research, since i didn't find them on their website. They replied within a day. Below is their response.

I was not able to upload the PDF document they had mailed me, so i am just adding the contents by copy & paste
-------------------------------------------------------------

Hello Gopi,

I'm responding to your inquiry about research progress updates. We are having trouble updating our website, so ...
Read more : Winter_2006_Progress_Summary from MRF | Views : 1456 | Replies : 0


Epratuzumab

Another one that's in phase III for lupus and they are talking about testing in other autoimmune diseases, including MS.



Immunomedics licenses drug to UCB

MAY. 10 - Business Week - Shares of Immunomedics Inc. jumped Wednesday when the biotech company said it agreed to license its lead product to Belgian biotech drug maker UCB for the treatment of immune system diseases.

Immunomedics shares rose 42 cents, or almost 15 percent, to $3.28 in morning ...
Read more : Epratuzumab | Views : 1705 | Replies : 1


Cytoxan and Novantrone

A research paper on Cytoxan and Novantrone.

<shortened url>

Both these treatments are cancer treatments. And also Campath and Caldribine are cancer drugs. This might be a stupid question - but what is cancer? Who says that MS isn't a blood cancer? It just seems odd that cancer treatments have some effect?

Ian
Read more : Cytoxan and Novantrone | Views : 1810 | Replies : 4


RPI-78M

Sounds like they are going to be starting a phase I/II MS trial soon.



Nutra Pharma Announces Approval to Start Late Phase II Human Trials in England

05/09/2006 -- Nutra Pharma Corp., a biotechnology company that is developing drugs for HIV and Multiple Sclerosis, has announced that their holding, ReceptoPharm, has received approval from the Medicines Health and Regulatory Agency (MHRA) for its application of human clinical trials for the treatment of Adrenomyeloneuropathy (AMN). The ...
Read more : RPI-78M | Views : 1587 | Replies : 0


CF101

This is primarily in testing for RA, but they are planning trials in MS patients too...



CanFite BioPharma aims to raise NIS 50 million

May 9, 2006 - Israel Business Arena Via Thomson Dialog NewsEdge - Drug development company Can Fite BioPharma Ltd. published a draft flotation prospectus on Sunday for the raising of NIS 30 million and a further NIS 20 million in a future offering through the exercising of warrants. Founded in 2000 ...
Read more : CF101 | Views : 1337 | Replies : 0


Rituxin

Just for information:

I've been corresponding with my 'good' neuro about EBV and MS. I mentioned that some PP sufferers on another site were reporting good results from Rituxin (anectodal stuff, but many claimed progression had been halted).

This neuro said he was hopeful about Rituxin as it targets B-cells - one of the places where EBV lives. Just his opinion - but it will be interesting to see if the trial results (interim results) ...
Read more : Rituxin | Views : 1596 | Replies : 0


nutrition

From early trial research it seems that it is possible to stop/slow the advance of MS from nutritional inputs. (Not vitamin or mineral supplements or any "left-field" products; food based only, normal produce) Additionally, these inputs lessen the severity of tremor related strikes and fatigue related to tremor related strikes. Seeking participants in larger clinical trial. Diet inputs only, no experimental drugs or drug regimes. Localized areas only.
Read more : nutrition | Views : 1365 | Replies : 0


BHT-3009 Phase II trial begins dosing

Bayhill doses patients with multiple sclerosis in phase II trial, raises $15.8M

Science Letter - May. 12, 2006

Bayhill Therapeutics, Inc., has begun dosing patients with BHT-3009, the company's experimental drug candidate, in a phase II company sponsored trial for multiple sclerosis.

The phase II study is a multicenter, double-blind, placebo-controlled evaluation with an MRI endpoint. In a related development, current investors indicated strong support for Bayhill's antigen-specific tolerance platform by raising an additional $15.8 ...
Read more : BHT-3009 Phase II trial begins dosing | Views : 1510 | Replies : 0


Phase III Trial of Oral Cladribine Starts

Phase III Trial of Oral Cladribine, a Novel Investigational Therapy for Multiple Sclerosis, Begins in the United States
Thursday May 4, 8:17 am ET
Nationwide Recruitment Begins at Sites Across the U.S.

ROCKLAND, Mass. and GENEVA, May 4 /PRNewswire-FirstCall/ -- Serono (virt-x: SEO and NYSE: SRA) announced today that recruitment in the U.S. is beginning for the Phase III CLARITY study (CLAdRIbine Tablets in Treating MS OrallY Study) of oral cladribine for the treatment of ...
Read more : Phase III Trial of Oral Cladribine Starts | Views : 2442 | Replies : 6


MBP8298

Not big news, but it's another hurdle jumped...



BioMS Medical's pivotal multiple sclerosis trial receives fourth positive review from Data Safety Monitoring Board

May 3 - CNW - BioMS Medical today announced that following the fourth meeting of the independent Data Safety Monitoring Board (DSMB), the Company has received a recommendation to continue its pivotal phase II/III clinical trial for MBP8298 for the treatment of secondary progressive multiple sclerosis.

"The recommendation by the independent DSMB ...
Read more : MBP8298 | Views : 3139 | Replies : 5


 

Login  •  Register


Statistics

Total posts 235158 • Total topics 25378 • Total members 16585


Contact us | Terms of Service